EXICURE, INC.
Exicure, Inc. (Nasdaq: XCUR) operates as a biotechnology company exploring strategic alternatives to maximize stockholder value. The company maintains its website at www.exicuretx.com and is headquartered in California with eight full-time employees as of December 31, 2025. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What EXICURE, INC. does
In the company’s own words
Exicure, Inc. (Nasdaq: XCUR) operates as a biotechnology company exploring strategic alternatives to maximize stockholder value. The company maintains its website at www.exicuretx.com and is headquartered in California with eight full-time employees as of December 31, 2025.
Historically, Exicure focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets using its proprietary spherical nucleic acid (SNA) technology platform. The company significantly restructured in September 2022, suspending preclinical activities and halting all research and development while exploring strategic alternatives. In September 2024, Exicure sold its historical biotechnology intellectual property and other assets, including SNA-related technology and clinical assets, to Flashpoint Therapeutics, Inc., recognizing $1.5 million in other income from this transaction.
The company's current strategic focus involves exploring growth through acquisitions and transactions with potential partners seeking to join an existing publicly-traded organization. In January 2025, Exicure acquired GPCR Therapeutics USA Inc., a subsidiary of Korean corporation GPCR Therapeutics Inc., and entered into a License and Collaboration Agreement to develop and commercialize GPCR's technologies. GPCR USA completed a Phase 2 clinical trial in January 2026 focused on blood cancer patients, with ongoing clinical trials involving GPC-100, a small molecule antagonist, combined with propranolol for stem cell mobilization in Multiple Myeloma patients.
In March 2025, Exicure formed KC Creation Co., Ltd., a wholly-owned South Korean subsidiary to explore collaboration opportunities and growth strategies, though management decided to sell this subsidiary in November 2025. The company also established a significant relationship with HiTron, which beneficially owns approximately 25 percent of outstanding common stock as of March 17, 2026, following common stock purchase agreements totaling $10 million in aggregate consideration.
Exicure currently generates no product revenue and relies on strategic partnerships and potential licensing arrangements for value realization. The company faces substantial doubt regarding its ability to continue as a going concern and requires significant additional capital to fund operations and pursue strategic alternatives. As of December 31, 2025, the company maintained approximately $3.7 million in cash and cash equivalents.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- CHICAGO, IL
- Fiscal year end
- December
- CIK
- 1698530
- SIC
- 2834
Financial performance, year by year
Fiscal 2017–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns EXICURE, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · EXICURE, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do EXICURE, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of EXICURE, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in EXICURE, INC.'s last four quarterly filings that the numbers alone won't show?”